ArticleBMC infectious diseases2025
Evaluation of hepatitis B vaccine effectiveness among fully vaccinated healthcare workers in Ethiopia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B vaccination is administered for Healthcare workers (HCWs) in three doses at 0, 1, and 6 months to provide immunity. However, in the study area, the effectiveness of the HBV vaccine remains uncertain.
objectiveThis study aimed to evaluate the effectiveness of the hepatitis B vaccine and identify factors influencing its effectiveness among fully vaccinated HCWs in all hospitals within East Gojjam Zone, Northwest Ethiopia. MATERIALS AND
methodsA hospital-based cross-sectional study was conducted among 422 HCWs from March to November 2024. Simple random sampling technique was used to recruit the study participants. Total sample size was allocated proportionally to each hospital. Five to seven milliliters of venous blood samples were collected and serum samples were analyzed to detect the anti-hepatitis B surface antigen (anti-HBs), hepatitis B surface antigen (HBsAg), and anti-hepatitis B core antibody (anti-HBc) using a sandwich enzyme-linked immunosorbent assay (ELISA). Data were analyzed using SPSS software version 25.
resultsOf fully vaccinated HCWs, 346/422 (82.0%) (95% CI: 78.0–86.0%) of them were sero-protected (had anti-HBs titer ≥ 10 mIU/ml). The concentration of protective anti-HBs (≥ 10 mIU/mL) was observed in 337/401 (84.0%) of non-smokers. The overall sero-positivity of HBsAg was 23/422 (5.5%) (95% CI: 3.0–8.0). Blood transfusion (AOR: 16.5, 95% CI: 1.53, 29.24) (P < 0.011) and dental extraction (AOR: 13.5, 95% CI: 3.99, 45.57) (P < 0.000) were significantly associated with HBsAg positivity. Moreover, the paradoxical co-existence of HBsAg and anti-HBs was 4.6% (95% CI: 2.0–7.0%). In addition, the overall sero-positivity of anti-HBc was 30/422 (7.1%) (95% CI: 5.0–10.0). Injectable medication (AOR: 4.3, 95% CI: 1.73, 10.72) (P < 0.002) was significant determinant for anti-HBc sero-positivity.
conclusionsThe study revealed suboptimal hepatitis B vaccine effectiveness, leading to intermediate HBV infection rates in the study area. These findings highlight the importance of monitoring post-vaccination anti-HBs antibody levels to address gaps in protection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.